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Introduction
!
Barrett’s esophagus (BE), defined as the presence
of specialized intestinal metaplasia (IM) in the
distal esophagus, is associated with an increased
risk of neoplastic progression [1]. In the past dec-
ades, endoscopic modalities have been developed
to treat early neoplastic lesions in order to pre-
vent progression to invasive esophageal adeno-
carcinoma [2]. Nodular lesions can be treated suc-
cessfully with endoscopic mucosal resection
(EMR) [3]. Various ablative techniques, including
radiofrequency ablation (RFA), photodynamic
therapy, and argon plasma coagulation (APC),
have been introduced to eradicate the BE mucosa,
which is harmful to the original normal squa-
mous epithelium, however, there is still room for
improvement [4–6].
Cryotherapy is a relatively new modality for the
endoscopic ablation of BE. Results based on a de-
vice using liquid nitrogen as cryogen have been
shown to be promising, with high rates of eradi-
cation of high grade dysplasia (HGD) and IM [7,
8]. Data on the use of pressurized carbon dioxide
(CO2) gas for cryoablation are scarce. Promising
results have been presented during conferences
[9,10]; however, apart from one pilot study in-
cluding patients with BE with or without low
grade dysplasia (LGD) [11], no results have been
published. The aim of this study was to determine
the efficacy and safety of cryospray ablation using
pressurized CO2 gas in the treatment of BE with
early neoplasia.
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Background: Cryotherapy is a relatively novel ab-
lation modality for the endoscopic ablation of
Barrett’s esophagus (BE). Data on the use of pres-
surized carbon dioxide (CO2) gas for cryoablation
are scarce.
Study aim: To determine the efficacy and safety of
cryospray ablation using pressurized CO2 gas in
the treatment of BE with early neoplasia.
Methods: In this prospective single center case se-
ries, we aimed to include 30 patients with BE and
early neoplasia. Nodular neoplastic lesions were
treated with endoscopic mucosal resection
(EMR). Residual BE mucosa was treated with
cryospray ablation every 4 weeks until the com-
plete BE segment was eliminated or up to seven
treatment sessions. If no reduction of the BE seg-
ment was observed after two subsequent treat-
ment sessions, cryoablation was terminated. Pa-
tients were contacted at days 1 and 4 post-treat-
ment to evaluate the level of discomfort. Endo-
scopic and histologic follow-up evaluations were
performed up to 24 months post-treatment.
Results: After the inclusion of 10 patients, insuffi-
cient effect of cryoablation was observed, result-
ing in early termination of the study. In total, sev-
en patients with intramucosal carcinoma (IMC)
and three with high grade dysplasia (HGD) were
included. Prior EMR was performed in nine pa-
tients. A median of 2.5 (IQR 2.0–4.0) cryoablation
sessions were performed. At 6 months of follow-
up, complete eradication of intestinal metaplasia
was observed in 11% (1/9; one patient died, not
treatment or disease related) of the patients and
complete eradication of dysplasia in 44% (4 /9). In
three patients, HGD or IMC was detected during
follow-up, and was endoscopically treated. Apart
from a gastric perforation as a result of gastric dis-
tension caused by CO2 gas during the first treat-
ment, cryospray treatments were well tolerated.
Conclusion: After a short learning curve, cryoa-
blation using CO2 gas was found to be a safe and
well tolerated treatment modality. However, in
our experience, the efficacy of CO2 cryoablation
combined with EMR for nodular lesions is disap-
pointing for the treatment of BE associated neo-
plasia.
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Patients and methods
!
In this prospective single center case series, we aimed to include
30 consecutive treatment naive patients with BE and HGD or in-
tramucosal carcinoma (IMC). The sample size of this pilot study
was not optimized for hypothesis testing but was based on pre-
vious cryoablation studies [7,11,12]. Since this is a post-market
study of a Food and Drug Administration approved device, which
was used in accordance with its “instructions for use” under con-
ditions of standard medical practice, no additional institutional
review board approval or trial registration was required accord-
ing to Dutch regulations.
Exclusion criteria were prior ablative or radiation therapy, and
surgery involving the esophagus. Nodular-appearing abnormal-
ities or lesions were first removed by a cap-assisted EMR proce-
dure.
The residual BE mucosa was treated with cryospray ablation
using pressurized CO2 gas as cryogen (Polar Wand, GI Supply,
Camp Hill, Pennsylvania, United States;●" Fig.1) within 3months
following EMR. The Polar Wand cryoablation device is Food and
Drug Administration approved for treatment of esophageal le-
sions. Informed consent was obtained from each patient. The
principle of CO2 cryoablation is based on repeated cycles of rapid
freezing and thawing, resulting in apoptosis and destruction of
the BE mucosa. The compressed CO2 gas is stored at room tem-
perature. A 7-French cryospray catheter is introduced through
the working channel and a suction catheter is attached to the tip
of the endoscope. The release of the pressurized CO2 gas at the
mucosal surface results in a rapid temperature drop to–78°C
(Joule Thompson effect) and subsequent freezing of the mucosa
(●" Fig.2). Cryospray ablation was performed at monthly inter-
vals until the complete BE segment was eliminated or up to seven
treatment sessions (●" Fig.3). If no reduction of the BE segment
Fig.1 The Polar Wand CO2 cryotherapy system. a The front of the porta-
ble system. b The tank with the compressed CO2 gas and the disposable
suction bottle at the back of the system, and the foot pedal to apply the gas
flow. c The 7-French flexible cryospray catheter, which is introduced
through the working channel of the endoscope.
Fig.2 Application of
the pressurized CO2
gas. a Endoscopic view
of the BE segment. b
The release of the pres-
surized CO2 gas results
in freezing of the muco-
sa. c After 20 seconds
of freezing, the CO2 re-
lease is interrupted, re-
sulting in thawing of
the mucosa.
Video 1
The tip of the cryospray catheter, introduced through the working channel of
the endoscope, is shown on the left. The release of the CO2 gas at the muco-
sal surface results in freezing of the BE tissue. Cryoablation for 20 seconds is
followed by active suctioning of the stomach to avoid extensive gastric dis-
tension.
online content including video sequences viewable at:
www.thieme-connect.de
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was observed after two subsequent treatment sessions, cryoabla-
tion was terminated to minimize the burden to patients. Cryoa-
blation treatments consisted of six applications with a CO2 cath-
eter per 2–3cm hemi-circumferential BE segment during 20 sec-
onds, with active suctioning of the stomach between applications
(●" Video 1, Supplementary Material). Midazolam or propofol
were used as sedative agents during the cryospray treatments.
All procedures were performed by two experienced endoscopists
(PS and FV). During the cryoablation phase, proton pump inhibi-
tors were prescribed in a dose of 40mg twice daily.
Patients were contacted on day 1 and day 4 post-treatment to
evaluate the level of discomfort using a questionnaire, which
was based on previous cryoablation studies [7,12]. Biopsies of
BE and neo-squamous epitheliumwere obtained from four quad-
rants at 1–2cm distance along the whole BE segment, either ex-
istent and/or ablated, before the 1st (following EMR), 4th, and 7th
treatment and at 3, 6, 12, 18, and 24 months post-treatment
using a disposable large capacity forceps. All histopathological
sections were evaluated by an expert pathologist (FK). EMR (of
nodular lesions) and APC were performed in the case of HGD or
IMC detection post-cryoablation.
The primary outcomemeasure was complete eradication of IM at
6 months of follow-up.Additional outcome measures were com-
plete eradication of dysplasia (including indefinite for dysplasia
(IFD), LGD and HGD) at 6 months of follow-up, complete eradica-
tion of IM and dysplasia at 12 and 24 months of follow-up, endo-
scopic reduction of the BE segment length, progression, and oc-
currence of adverse events. Patients with complete eradication
of IM also had dysplasia completely eradicated andwere included
in both end points.
Results
!
After the inclusion of 10 patients between January 2011 and Sep-
tember 2011, insufficient effect of cryoablation was observed,
which resulted in the decision to terminate the inclusion of pa-
tients early. In total, seven patients with IMC and three with
HGD were included with a mean age (± standard deviation (SD))
of 71 (±9) years. Before cryoablation, a single EMR procedure was
performed in nine patients. No nodular lesions were observed
following EMR, before cryospray treatments. Pre-cryoablation di-
agnoses were IM (n=4), LGD (n=5), and HGD (n=1). A median of
2.5 (interquartile range (IQR) 2.0–4.0) cryoablation sessions
were performed. Cryoablation treatments were terminated
when the BE segment was completely eradicated in two patients,
when the maximum of seven treatments was performed in two
patients, when no effect was observed after two subsequent
treatment sessions in five patients, and when treatment was
complicated by a gastric perforation in one patient. Propofol was
used in 9 of the 32 cryospray procedures in a total of three pa-
tients. In the remaining cryoablation treatments, patients were
sedated with Midazolam. A non-significant reduction of the BE
segment length was observed following cryoablation treatments
5.0 (IQR 1.8–7.3) cm pre-cryoablation vs. 2.5 (IQR 0.9–6.3) cm 3
months post-cryoablation, P=0.08).
Three patients died and were subsequently censored and exclud-
ed from data analysis at 6 (n=1) and 24 months (n=2) of follow-
up.Their causes of death were not related to esophageal neopla-
sia or cryoablation treatment but were the result of pneumonia,
primary lung cancer, and necrotizing fasciitis after resection of a
skin lesion. Complete eradication of IMwas observed in 11% (1/9;
one patient died) and complete eradication of dysplasia in 44%
Month Phase Endoscopy
Baseline
endoscopy + BxBaseline– 4 to 0
EMR visible
lesions + BxEMR– 3 to 0
0
Cryoablation
phase
Termination of cryospray 
treatments in case of:
– complete eradication of BE
– no effect after 2 subsequent  
 treatments
Bx: HGD/IMC
EMR (nodular lesions)
or APC
Surveillance
phase
Bx + Cryospray 1
1 Cryospray 2
2 Cryospray 3
3 Bx + Cryospray 4
4 Cryospray 5
5 Cryospray 6
6 Bx + Cryospray 7
+ 3 Endosc. + Bx
+ 6 Endosc. + Bx
+ 12 Endosc. + Bx
+ 18 Endosc. + Bx
+ 24 Endosc. + Bx
Fig.3 Flow chart of the cryoablation study proto-
col. Following removal of nodular lesions by EMR in
patients with HGD or IMC, cryospray ablation was
performed at monthly intervals until the complete
BE segment was eliminated or up to seven treat-
ment sessions. At 3, 6, 12, 18, and 24 months post-
treatment, follow-up endoscopies with biopsies
were performed. EMR (of nodular lesions) and APC
were performed if HGD or IMC were detected post-
cryoablation. Legend: Bx=biopsies; Endosc=endos-
copy.
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(4 /9) of the patients at 6 months of follow-up (●" Fig.4). In three
patients, HGD or IMC was detected during follow-up, which was
treatedwith EMR (n=3; at 6 months of follow-up) and APC (n=1;
at 24 months of follow-up) (●" Table1). Complete eradication of
IM and dysplasia at 12 and 24 months of follow-up was affected
by treatment performed in these three patients with progression
(●" Fig.4). No buried BE glands were detected in the ablated seg-
ments during follow-up. In one patient, a longitudinal perfora-
tion along the lesser curvature of the stomach was detected 1
day after the first ablation treatment, comprising six cryospray
applications of a hemi-circumferential BE segment of 1cm. Fol-
lowing surgical intervention, no further cryoablationwas applied
in this patient. In another two patients, the first cryoablation
treatment was complicated by a superficial esophageal laceration
without the need for intervention. In 6/32 (19%) cryospray treat-
ments, patients complained of mild retrosternal pain and in 6/32
(19%) and 7/32 (22%) of self-limiting odynophagia and dyspha-
gia, respectively, in the first 1 to 4 days post-treatment. No stric-
tures were detected.
Discussion
!
Various endoscopic therapies have been developed for the abla-
tion of BE. Cryotherapy is a relatively new non-contact ablative
modality with two different systems based on liquid nitrogen or
pressurized CO2 gas. This is the first report on the use of cryoabla-
tion based on pressurized CO2 combined with EMR for nodular
lesions in the treatment of BE associated neoplasia. In our experi-
ence, the effect of CO2 cryotherapy was disappointing, with com-
plete eradication of IM and dysplasia at 6 months of follow-up in
only 11% and 44% of the patients, respectively. Additionally, HGD
or IMC was detected at 6 months of follow-up in 33% of patients.
Based on the time after initial treatment, these are most likely
“incident” cancers as a result of progression during and after
cryoablation. However, it cannot be excluded that these may
have been missed during prior endoscopy despite extensive
endoscopic and biopsy protocols; in that case, these lesions
should be classified as “prevalent cancers”. The inclusion of pa-
tients was terminated prematurely because of insufficient effica-
cy.
Only one previous study has been published using pressurized
CO2 for the ablation of BE and associated LGD [11]. Xue et al. re-
ported complete eradication of LGD in 100% (6 /6) and complete
eradication of IM in 85% (17/20) of the cases at 6 months of fol-
low-up in a prospective case series. Possible explanations for the
better outcome in the study by Xue et al. may be the inclusion of
cases with only BE and LGD with shorter BE segments, which
may be, at least theoretically, easier to ablate, the relatively short
follow-up period, the less thorough follow-up biopsy protocol,
the presence of persistent endoscopic signs of BE in the majority
of cases but with eradication of IM at histologic evaluation, and
the younger and Asian study population. Additionally, CO2 dosi-
metry was not clearly documented by Xue et al.
In contrast, results based on the liquid nitrogen device (CSAMed-
ical Inc, Baltimore, Maryland, United States) are promising. Three
studies using this system, both single-center and multi-center
with relatively large patient samples (n=30–98), have been pub-
lished [7,8,12]. Dumot et al. included inoperable patients with BE
and HGD or IMC and demonstrated downgrading of the histopa-
thology stage in 68% of HGD and 80% of IMC patients after cryoa-
blation treatment during a median follow-up period of 12
months [12]. Others showed complete eradication of HGD in
97–100% of the patients, complete eradication of all dysplasia
in 87% and complete eradication of IM in 57–84% during amedi-
an follow-up of 10 months to 24 months [7,8].
The device used in these studies delivers liquid nitrogen at a tem-
perature of –196°C at the mucosa [7,8,12], while mucosal freez-
ing is achieved at–78°C using the pressurized CO2 system. It may
well be that the relatively “less cold” temperature with CO2
cryoablation affects the depth and degree of mucosal injury.
Studies comparing the two types of cryoablation devices have
not been performed.
CO2 dosimetry in our study was based on previous cryoablation
studies and on testing experiments in a pig model resulting in
mucosal, submucosal, and transmural necrosis following 15, 30,
and 120 seconds, respectively, of cryoablation [7–13]. We as-
sumed that repeated cycles of 20 seconds of cryospray treatment
would ablate the completemucosal layer in BE. A longer period of
continuous CO2 cryospray ablation is not recommended as the
gas inflated at a flow of 8L/min results in considerable gastric
distension. The effect of the suction catheter attached to the tip
of the endoscope is only minimal.
The first treatment session in our study was complicated by gas-
tric perforation and a gastric and esophageal laceration. We are
convinced that this can be attributed to the learning curve, with
extra time needed to adequately position the catheter to achieve
the ice-effect, which resulted in the accumulation of more CO2
gas and increased gastroesophageal distension. Perforation may
be prevented by accurate positioning of the cryospray catheter
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Fig.4 Complete eradi-
cation of dysplasia and
intestinal metaplasia
(IM) following cryoabla-
tion treatments.
a, b Proportion of pa-
tients with complete
eradication of dysplasia
and IM at 6 months and
12 months post-cryo-
ablation, respectively;
total number of pa-
tients: 9; one patient
died. c Complete eradi-
cation of dysplasia and
IM at 24 months post-
cryoablation; total
number of patients: 7;
three patients died.
Results at 12 and 24
months of follow-up
were affected by EMR
performed at 6 months
of follow-up in three pa-
tients with progression.
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before activation of the gas flow, and by limiting the duration of
CO2 spraying to 20 seconds per application, which reduces accu-
mulation of CO2 gas and subsequent distension of the esophagus
and stomach. Active suctioning of the stomach between cryos-
pray applications was included in the study protocol to limit the
perforation risk. Besides gastric perforation, cryospray treat-
ments were well tolerated, with only mild retrosternal pain, ody-
nophagia, and dysphagia in a minority of the patients, which is
comparable to the number of adverse events reported by Xue et
al. [11]. Additionally, no strictures were detected in both CO2
cryotherapy studies. In studies using liquid nitrogen cryoabla-
tion, strictures and severe retrosternal pain were reported in a
small number of patients [7, 8], again suggesting more severe
mucosal injury with liquid nitrogen cryoablation compared to
CO2 cryoablation.
The advantages of CO2 cryoablation are the lower costs and the
ease in controlling the endoscope because of less stiffness and
cold when compared to the liquid nitrogen device. Advantages
of cryoablation above RFA are the non-contact method facilitat-
ing ablation of the irregularly lined mucosa, the adjustable dosi-
metry, the lower costs and, by no means least, cryoablation is
considered less painful [14, 15].
In conclusion, after a short learning curve, cryoablation using CO2
gas was found to be a safe andwell-tolerated treatment modality.
However, in our experience, the efficacy of CO2 cryoablation
combined with EMR for nodular lesions is disappointing for the
treatment of BE associated neoplasia.
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